{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:13:48Z","timestamp":1759940028259},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 64-year-old man with castration-resistant prostate cancer received <jats:sup>223<\/jats:sup>Ra injection to treat bone metastases. The patient underwent a <jats:sup>223<\/jats:sup>Ra SPECT scan after the first <jats:sup>223<\/jats:sup>Ra injection in which there was increased uptake all over the spine. Spine-to-background activity ratio in the patient was approximately three times greater than normal spine-to-background activity ratios in <jats:sup>223<\/jats:sup>Ra SPECT obtained from the other patients. Eight days after the fifth injection, the patient exhibited a very poor neurologic examination and died of intracranial hemorrhage due to severe thrombocytopenia (platelet counts, 23,000\/mm<jats:sup>3<\/jats:sup>). The extensive radiation to the spine may have enhanced myelophthisic process in this case.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002117","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T02:15:16Z","timestamp":1525918516000},"page":"546-547","source":"Crossref","is-referenced-by-count":4,"title":["Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride"],"prefix":"10.1097","volume":"43","author":[{"given":"Tadaki","family":"Nakahara","sequence":"first","affiliation":[{"name":"Radiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Owaki","sequence":"additional","affiliation":[{"name":"Radiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Urology, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Fukada","sequence":"additional","affiliation":[{"name":"Radiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Radiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Jinzaki","sequence":"additional","affiliation":[{"name":"Radiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-017-0330-z","article-title":"Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience","volume":"7","year":"2017","journal-title":"EJNMMI Res"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2014.12.061","article-title":"Radium-223 in the treatment of osteoblastic metastases: a critical clinical review","volume":"91","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/RLU.0b013e3182a2dd53","article-title":"New treatment option: 223Ra chloride, the first approved unsealed \u03b1-emitting radiopharmaceutical","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00259-015-3150-2","article-title":"Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/MNM.0b013e328353bb6e","article-title":"Quantitative imaging of 223Ra-chloride (alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases","volume":"33","year":"2012","journal-title":"Nucl Med Commun"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/RLU.0000000000001909","article-title":"High-energy collimator is preferable to medium-energy collimator for evaluating 223Ra uptake in bone metastasis at 2 weeks postinjection","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","article-title":"Dosimetry of 223Ra-chloride: dose to normal organs and tissues","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201807000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:04:59Z","timestamp":1695618299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201807000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002117","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}